Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Stock Position Lifted by AustralianSuper Pty Ltd

AustralianSuper Pty Ltd lifted its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 15.7% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 4,218 shares of the biopharmaceutical company’s stock after purchasing an additional 573 shares during the quarter. AustralianSuper Pty Ltd’s holdings in Alnylam Pharmaceuticals were worth $993,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently modified their holdings of the company. Jennison Associates LLC bought a new position in shares of Alnylam Pharmaceuticals in the fourth quarter worth $61,160,000. Strategic Financial Concepts LLC acquired a new stake in shares of Alnylam Pharmaceuticals in the fourth quarter valued at $41,529,000. Los Angeles Capital Management LLC lifted its holdings in shares of Alnylam Pharmaceuticals by 11,433.4% in the third quarter. Los Angeles Capital Management LLC now owns 137,017 shares of the biopharmaceutical company’s stock valued at $37,684,000 after buying an additional 135,829 shares during the period. Assenagon Asset Management S.A. lifted its holdings in shares of Alnylam Pharmaceuticals by 13.0% in the fourth quarter. Assenagon Asset Management S.A. now owns 19,918 shares of the biopharmaceutical company’s stock valued at $4,687,000 after buying an additional 2,285 shares during the period. Finally, Sumitomo Mitsui Trust Group Inc. lifted its holdings in shares of Alnylam Pharmaceuticals by 3.0% in the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 286,703 shares of the biopharmaceutical company’s stock valued at $67,464,000 after buying an additional 8,462 shares during the period. Institutional investors own 92.97% of the company’s stock.

Insider Activity

In other news, CEO Yvonne Greenstreet sold 5,219 shares of the stock in a transaction dated Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total transaction of $1,309,864.62. Following the transaction, the chief executive officer now owns 78,880 shares of the company’s stock, valued at approximately $19,797,302.40. This represents a 6.21 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CMO Pushkal Garg sold 52,592 shares of the stock in a transaction that occurred on Monday, January 27th. The shares were sold at an average price of $285.00, for a total value of $14,988,720.00. Following the sale, the chief marketing officer now owns 11,989 shares of the company’s stock, valued at approximately $3,416,865. The trade was a 81.44 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 73,964 shares of company stock valued at $20,622,925. Insiders own 1.50% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on ALNY. Sanford C. Bernstein cut their price objective on Alnylam Pharmaceuticals from $314.00 to $310.00 and set an “outperform” rating for the company in a report on Tuesday, January 7th. Scotiabank cut their price objective on Alnylam Pharmaceuticals from $310.00 to $300.00 and set a “sector outperform” rating for the company in a report on Friday. HC Wainwright reaffirmed a “buy” rating and set a $400.00 target price on shares of Alnylam Pharmaceuticals in a report on Monday, January 13th. Chardan Capital reaffirmed a “buy” rating and set a $300.00 target price on shares of Alnylam Pharmaceuticals in a report on Friday, November 1st. Finally, William Blair reaffirmed an “outperform” rating on shares of Alnylam Pharmaceuticals in a report on Tuesday, November 19th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and nineteen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Alnylam Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $299.43.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY stock opened at $256.45 on Friday. The company has a debt-to-equity ratio of 31.64, a current ratio of 2.75 and a quick ratio of 2.69. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $141.98 and a fifty-two week high of $304.39. The stock’s 50-day moving average is $254.03 and its two-hundred day moving average is $263.35. The firm has a market cap of $33.08 billion, a P/E ratio of -97.88 and a beta of 0.35.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.03). Analysts predict that Alnylam Pharmaceuticals, Inc. will post -2.24 earnings per share for the current fiscal year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.